Showing 1371-1380 of 2656 results for "".
- OD-OS Releases Software Update For the Computer-Guided Navilas 577s Laser Systemhttps://modernod.com/news/od-os-releases-software-update-for-the-computer-guided-navilas-577s-laser-system/2480112/OD-OS has released a comprehensive software update for the computer-guided Navilas 577s Laser System. New functionalities of software release 3.4 make the tissue-friendly treatment of retinal diseases using navigated microsecond laser pulses more intuitive, predictable, and reproducible, accordin
- Fauci Says He’s ‘Cautiously Optimistic’ About Moderna COVID-19 Vaccinehttps://modernod.com/news/fauci-says-hes-cautiously-optimistic-about-moderna-covid-19-vaccine/2477860/Infectious disease expert Anthony Fauci, MD, says he’s “cautiously optimistic” about biotech company Moderna’s COVID-19 vaccine candidate, according to a FierceHealthcare
- China Gives Green Light to Allergan’s Xen Registration for the Surgical Management of Refractory Glaucomahttps://modernod.com/news/china-gives-green-light-to-allergans-xen-registration-for-the-surgical-management-of-refractory-glaucoma/2477514/Allergan announced China’s National Medical Products Administration (NMPA) approved the registration of Allergan’s Xen Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma. Xen is th
- OneSight Seeks Volunteer ODs for Charitable Clinicshttps://modernod.com/news/onesight-seeks-volunteer-ods-for-charitable-clinics/2479133/OneSight, which provides vision care access to more than 50 million people globally through charitable vision clinics and permanent vision centers, is in need of optical professionals to volunteer their skills to help reach the 1.1 billion people worldwide who lack access to eye exams and glasses
- Roche’s Actemra/RoActemra Paired With Gilead’s Remdesivir in COVID-19 Pneumonia Studyhttps://modernod.com/news/roches-actemra-roactemra-paired-with-gileads-remdesivir-in-covid-19-pneumonia-study/2477839/Roche said that it has initiated a phase 3 study in collaboration with Gilead Sciences to investigate the efficacy of the anti-IL-6 receptor biologic Actemra/RoActemra (tocilizumab) in combination with remdesivir in hospitalized patients with severe COVID-19 pneumonia. The REMDACTA trial will com
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We
- iOR Partners Co-Founder and Chairman of the Board, Daniel S. Durrie, MD, Retireshttps://modernod.com/news/ior-partners-co-founder-and-chairman-of-the-board-daniel-s-durrie-md-retires/2482267/iOR Partners announced the retirement of Daniel S. Durrie, MD, as Chairman of the Board of Directors. Dr. Durrie co-founded iOR Partners, a provider of ophthalmic office-based surgery (OBS), in 2018. iOR's model provides surgeons with turnkey OBS suites and support service
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- Pfizer, BioNTech’s COVID-19 Vaccine Neutralizes Brazil Variant in Lab Studyhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-neutralizes-brazil-variant-in-lab-study/2478953/According to laboratory study findings published Monday in the NEJM, Pfizer and BioNTech’s mRNA-based COVID-19 vaccine BNT162b2 was able to neutralize the P.1 variant of SARS-CoV-2 that first surfaced in Brazil. The news follows a report late last week that suggested AstraZeneca’s cor
- Real-World Use Analysis Backs Efficacy of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/real-world-use-analysis-backs-efficacy-of-pfizer-biontechs-covid-19-vaccine/2478875/Results from real-world use of Pfizer and BioNTech’s BNT162b2 show that two doses of the mRNA-based vaccine can cut the number of symptomatic COVID-19 infections by 94%, whilst also reducing severe illness by 92%. The Clalit Research Institute’s preliminary findings come from an analy